Plain-English translation of NCT05824923 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new procedure called pulmonary artery denervation (PADN) for people with heart failure who also have high blood pressure in their lungs. In the study, some participants will receive the PADN procedure along with their regular heart failure medications, while others will continue with medications alone. Researchers will follow both groups for 3 years to see if the procedure helps patients feel better and reduces complications.
Many people with heart failure develop dangerously high blood pressure in their lungs, which makes their symptoms worse and can be life-threatening even when they are taking all recommended medications. This trial is testing whether this new treatment can help when medications alone aren't enough.
If you enroll, you will be randomly assigned to either receive the PADN procedure plus your regular heart failure medications, or to continue with medications alone. The PADN procedure is minimally invasive and performed by a cardiologist. You will visit the clinic for the procedure itself, and then return for follow-up visits over 3 years so doctors can monitor your heart function, symptoms, and overall health. Control group participants who still qualify can choose to receive the procedure after 12 months if they wish.
AI-generated summary from trial data · Aug 1, 2026 · Not medical advice
China